drugset / Trial / NCT02659150
Effect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis
Phase 4
Terminated
16 enrolled
Massachusetts General Hospital
Brigham and Women's Hospital · collabGenentech, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the hypothesis that anti-IL-6 therapy is effective for reducing plaque inflammation as measured by fluorine-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with rheumatoid arthritis (RA) who are synthetic disease-modifying antirheumatic drugs (dMARD) inadequate responders and are naive to biologic therapy.
Timeline
- Start
- 2016-05-18
- Primary completion
- 2019-11-16
- Completion
- 2019-11-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tocilizumab | Monoclonal antibody | 162 mg | Subcutaneous |